Exploring the targeted delivery of biopharmaceuticals enabled by glycosylation c...
Exploring the targeted delivery of biopharmaceuticals enabled by glycosylation control
Most biotechnological therapeutics used in the clinic today and under current development, are of protein nature. Eukaryotic expression systems (such as yeasts and mammalian cells) for these therapeutic proteins add carbohydrate m...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BIO2009-08983
DESARROLLO DE UNA PLATAFORMA UNIVERSAL DE GLICOSONDAS PARA D...
97K€
Cerrado
IJCI-2017-32874
Glycosyltransferases as drug targets and their implication i...
64K€
Cerrado
PRE2020-093759
INGENIERIA DE PROTEINAS E INGENIERIA METABOLICA DE GLICOZIMA...
99K€
Cerrado
ISOS
ISOS Implantable Ecosystems of Genetically Modified Bacteria...
2M€
Cerrado
RTI2018-095214-B-I00
ESTUDIO IN VIVO DE TERAPIAS MOLECULARES DE DISEÑO Y UN NANO-...
121K€
Cerrado
Información proyecto GlycoTarget
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Most biotechnological therapeutics used in the clinic today and under current development, are of protein nature. Eukaryotic expression systems (such as yeasts and mammalian cells) for these therapeutic proteins add carbohydrate moieties (glycans) to the proteins, and these glycans strongly modulate the protein's in vivo biodistribution and therapeutic efficacy. Until recently, no adequate tools were available to accurately control glycosylation structure in these expression systems, but bio-engineering research in our lab and elsewhere has now largely overcome this problem.
In the GlycoTarget ERC Consolidator grant project, we aim at exploring the relation between the structure of the glycans on therapeutic proteins and the in vivo targeting properties of these modified proteins to different tissues/cells/subcellular organelles.
As highly medically relevant test cases for this exploration, we have selected three diseases with strong unmet therapeutic need, that could potentially be treated with glyco-targeted biopharmaceuticals through three different routes of protein delivery: progressive liver disease (intravenous), allergic asthma (subcutaneous immunization) and active tuberculosis (intrapulmonary delivery).